Related Experiment Video
Updated: Nov 10, 2025

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
Published on: May 5, 2023
Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of
Yujiro Matsuishi1,2,3, Bryan J Mathis4, Nobutake Shimojo1
1Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
Insights
COVID-19 can cause severe organ damage through endothelial dysfunction, leading to conditions like ARDS and multi-organ failure. Therapies targeting endothelial function may improve patient outcomes.
Area of Science:
- Cardiovascular Science
- Infectious Diseases
- Pathology
Background:
- The COVID-19 pandemic has highlighted severe health complications beyond respiratory issues.
- Endothelial dysfunction is implicated in the exacerbation of COVID-19 by chronic conditions like diabetes and cardiovascular disease.
- Excessive inflammation in COVID-19 contributes to acute respiratory distress syndrome (ARDS) and multi-organ dysfunction syndrome (MODS).
Purpose of the Study:
- To review the impact of immune-mediated endothelial dysfunction on organ injuries in COVID-19 patients.
- To discuss the mechanisms leading to multi-organ dysfunction in severe COVID-19.
- To explore potential therapeutic strategies targeting endothelial dysfunction and bradykinin storm.
Main Methods:
- Literature review and synthesis of existing research on COVID-19 pathophysiology.
- Analysis of studies detailing organ-specific injuries (heart, brain, kidney, liver) in COVID-19.
- Discussion of pharmacological interventions for endothelial dysfunction.
Main Results:
- COVID-19 is associated with significant heart injuries, ischemic stroke, hemorrhage, acute kidney injury, and liver injury.
- Immune-mediated endothelial dysfunction is a key factor in the development of multi-organ dysfunction syndrome in COVID-19.
- Excessive inflammation, thrombosis, and disseminated intravascular coagulation (DIC) contribute to mortality.
Conclusions:
- Maintaining endothelial integrity is critical for improving prognosis in COVID-19 patients.
- Therapeutic interventions aimed at improving endothelial function show promise.
- Angiotensin receptor blockers and ACE inhibitors may offer benefits by addressing endothelial dysfunction and bradykinin storm.
Abstract:
Since December 2019, the SARS-CoV-2 (COVID-19) pandemic has transfixed the medical world. COVID-19 symptoms vary from mild to severe and underlying chronic conditions such as pulmonary/cardiovascular disease and diabetes induce excessive inflammatory responses to COVID-19 and these underlying chronic diseases are mediated by endothelial dysfunction. Acute respiratory distress syndrome (ARDS) is the most common cause of death in COVID-19 patients, but coagulation induced by excessive inflammation, thrombosis, and disseminated intravascular coagulation (DIC) also induce death by multiple-organ dysfunction syndrome. These associations imply that maintaining endothelial integrity is crucial for favorable prognoses with COVID-19 and therapeutic intervention to support this may be beneficial. Here, we summarize the extent of heart injuries, ischemic stroke and hemorrhage, acute kidney injury, and liver injury caused by immune-mediated endothelial dysfunction that result in the phenomenon of multi-organ dysfunction seen in COVID-19 patients. Moreover, the potential therapeutic effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors that improve endothelial dysfunction as well as the bradykinin storm are discussed.
More Related Videos
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
06:35Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Myocarditis I: Introduction
Endocarditis III: Medical Management
Myocarditis III: Medical Management